Predictive Value of Nasal Nitric Oxide and Serum NOS2 Levels in the Efficacy of Subcutaneous Immunotherapy in Pediatric Patients with Allergic Rhinitis

Table 1

Demographics and clinical characteristics of patients between two groups.

Variables	AR group ()	HC group ()	value
Sex			0.647
Male	55 (45.8%)	20 (50.0%)
Female	65 (54.2%)	20 (50.0%)
Age, years			0.480
BMI, kg/m^2			0.215
Smoking	20 (16.7%)	8 (20.0%)	0.631
Alcohol consumption	10 (8.3%)	6 (15.0%)	0.362
nNO, ppb			<0.001
Serum NOS2(IU/ml)			<0.001
Disease duration, years	4.6 ± 2.6	—	—
Allergic comorbidities
AS	28 (23.3%)	0 (0.0%)	0.001
AC	22 (18.3%)	0 (0.0%)	0.004
Baseline VAS	5.8 ± 3.5	—	—
Baseline TNSS	7.6 ± 2.8	—	—

BMI: body mass index; nNO: nasal nitric oxide; ppb: parts per billion; AS: allergic asthma; AC: allergic conjunctivitis; TNSS: total nasal symptom score; VAS: visual analogue scale.